deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03963232

A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine (PERSIST)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study

Sponsor: Eli Lilly and Company

Conditions Episodic Migraine
Interventions Galcanezumab Placebo
Updated 28 times since 2019 Last updated: Mar 1, 2023 Started: Jul 30, 2019 Primary completion: Jul 27, 2021 Completion: Mar 11, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Episodic Migraine, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 28 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

28 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Sep 2022 — Apr 2023 [monthly]

    Completed PHASE3

▶ Show 23 earlier versions

  1. May 2022 — Sep 2022 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE3

  3. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE3

  5. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  8. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  9. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  10. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  11. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  12. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  13. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  14. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  15. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE3

  16. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

  17. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE3

  18. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE3

  19. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  20. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  21. Aug 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE3

  22. Jul 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE3

  23. Jun 2019 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Baotou, China , Beijing, China , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China , Guangzhou, China , Guiyang, China , Gurgaon, India and 22 more locations